Modified irinotecan plus bolus 5-fluorouracil/L-leucovorin for metastatic colorectal cancer at a single institution in Japan (vol 43, pg 842, 2008)

被引：0
|
作者：
Suenaga, Mitsukuni [1 ]
Mizunuma, Nobuyuki [1 ]
Shouji, Daigo [1 ]
Shinozaki, Eiji [1 ]
Matsusaka, Satoshi [1 ]
Chin, Keisho [1 ]
Oya, Masatoshi [2 ]
Yamaguchi, Toshiharu [2 ]
Muto, Tetsuichiro [2 ]
Hatake, Kiyohiko [1 ]
机构：
[1] Canc Inst Hosp, Dept Med Oncol, Japanese Fdn Canc Res, Koto Ku, Tokyo 1358550, Japan
[2] Canc Inst Hosp, Div Gastroenterol Surg, Japanese Fdn Canc Res, Tokyo 1358550, Japan
来源：
JOURNAL OF GASTROENTEROLOGY | 2009年 / 44卷 / 07期
关键词：
D O I：
10.1007/s00535-009-0079-x
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：801 / 801
页数：1
相关论文
共 50 条
  • [41] Bevacizumab in combination with irinotecan, 5-fluorouracil and leucovorin given as first-line treatment of metastatic colorectal cancer
    Rocha, Jose Aurillo
    ANTI-CANCER DRUGS, 2011, 22 : S9 - S13
  • [42] Bimonthly leucovorin, infusion 5-fluorouracil, hydroxyurea, and irinotecan (FOLFIRI-2) for pretreated metastatic colorectal cancer
    Mabro, M
    Louvet, C
    André, T
    Carola, E
    Gilles-Amar, V
    Artru, P
    Krulik, M
    de Gramont, A
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2003, 26 (03): : 254 - 258
  • [43] A Phase II study of ANGIOZYME® in combination with 5-fluorouracil, leucovorin and irinotecan in the treatment of metastatic colorectal cancer patients
    Usman, N
    Venook, A
    Hurwitz, H
    Cunningham, C
    Fuchs, C
    Burris, H
    Schwartzberg, L
    Pelley, R
    Miller, WH
    Modiano, M
    EUROPEAN JOURNAL OF CANCER, 2002, 38 : S72 - S72
  • [44] Posterior Reversible Encephalopathy Syndrome During Treatment with Aflibercept, 5-Fluorouracil, Leucovorin, and Irinotecan for Metastatic Colorectal Cancer
    Nikolaos Miaris
    Joseph Sgouros
    Margarita Gerolympou
    Basilios Spyropoulos
    Dionysios Drakopoulos
    Stefania Gkoura
    Helen Res
    Epaminondas Samantas
    Journal of Gastrointestinal Cancer, 2019, 50 : 123 - 126
  • [45] 5-FLUOROURACIL PLUS HIGH-DOSE LEUCOVORIN FOR THERAPY OF 5-FLUOROURACIL-RESISTANT METASTATIC COLORECTAL-CANCER
    OSTERWALDER, B
    SCHMID, L
    JUNGI, WF
    SENN, HJ
    BLUT, 1988, 57 (04): : 207 - 207
  • [46] Clinical trial of low-dose leucovorin plus 5-fluorouracil for patients with metastatic colorectal cancer
    Yamaguchi, Yoshiyuki
    Sawamura, Akihiro
    Minami, Kazuhito
    HEPATO-GASTROENTEROLOGY, 2007, 54 (77) : 1394 - 1397
  • [47] Randomized phase II/III study of 5-fluorouracil/l-leucovorin versus 5-fluorouracil/l-leucovorin plus paclitaxel administered to patients with severe peritoneal metastases of gastric cancer (JCOG1108/WJOG7312G)
    Nakajima, Takako Eguchi
    Yamaguchi, Kensei
    Boku, Narikazu
    Hyodo, Ichinosuke
    Mizusawa, Junki
    Hara, Hiroki
    Nishina, Tomohiro
    Sakamoto, Takeshi
    Shitara, Kohei
    Shinozaki, Katsunori
    Katayama, Hiroshi
    Nakamura, Shinichiro
    Muro, Kei
    Terashima, Masanori
    GASTRIC CANCER, 2020, 23 (04) : 677 - 688
  • [48] THE BUDGETARY IMPACT OF GENETIC-GUIDED DOSING OF 5-FLUOROURACIL, IRINOTECAN, LEUCOVORIN, AND BEVACIZUMAB (FOLFIRI plus BEV) IN METASTATIC COLORECTAL CANCER (MCRC)
    Rivers, Z.
    Stenehjem, D.
    Jacobson, P.
    Lou, E.
    Nelson, A.
    Kuntz, K. M.
    VALUE IN HEALTH, 2020, 23 : S42 - S42
  • [49] Phase II study of infusional 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) plus bevacizumab as first-line treatment for metastatic colorectal cancer
    Kopetz, S.
    Glover, K. Y.
    Eng, C.
    Wolff, R. A.
    Chang, D. Z.
    Adinin, R. B.
    Morris, J.
    Abbruzzese, J. L.
    Hoff, P. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [50] Randomised phase II evaluation of irinotecan plus high-dose 5-fluorouracil and leucovorin (ILF) vs 5-fluorouracil, leucovorin, and etoposide (ELF) in untreated metastatic gastric cancer
    M Moehler
    A Eimermacher
    J Siebler
    T Höhler
    A Wein
    M Menges
    D Flieger
    T Junginger
    T Geer
    E Gracien
    P R Galle
    M Heike
    British Journal of Cancer, 2005, 92 : 2122 - 2128
12345